This course has expired. View available courses.
Endocrinology, Medication Management
GLP-1 receptor agonists and CV risk: what do GPs need to know?
While the majority of people with type 2 diabetes (T2D) do not have established cardiovascular disease (CVD), most are at risk for a cardiovascular (CV) event. In recognition of this significant risk, international and local guidelines recommend that the focus of T2D management move beyond glycaemic control to include comprehensive CV risk management. According to these guidelines, GLP-1 receptor agonists indicated for cardioprotection should now be considered in patients with T2D and established CV disease or in those without established CVD but with multiple CV risk factors.
This 1-hour RACGP accredited activity aims to enable GPs to confidently select patients with T2D who might benefit from initiation of a GLP-1 receptor agonist as first injectable therapy.
This program is supported by an independent educational grant provided from Eli Lilly.
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
RACGP CPD Program
EXPIRY DATE
2022-09-07
While the majority of people with type 2 diabetes (T2D) do not have established cardiovascular disease (CVD), most are at risk for a cardiovascular (CV) event. In recognition of this significant risk, international and local guidelines recommend that the focus of T2D management move beyond glycaemic control to include comprehensive CV risk management. According to these guidelines, GLP-1 receptor agonists indicated for cardioprotection should now be considered in patients with T2D and established CV disease or in those without established CVD but with multiple CV risk factors.
This 1-hour RACGP accredited activity aims to enable GPs to confidently select patients with T2D who might benefit from initiation of a GLP-1 receptor agonist as first injectable therapy.
This program is supported by an independent educational grant provided from Eli Lilly.
Faculty
Anita Sharma, GP (QLD)
Tom Dover, Endocrinologist (QLD)
Peter Purnell, Cardiologist (WA)
Learning objectives
On completion of this program, GPs will be better able to:
- Recall the latest clinical data on the CV benefits of specific GLP-1 receptor agonists
- Describe how the latest clinical data has impacted management recommendations for patients with T2D who are uncontrolled on metformin
- Re-evaluate existing patients and treatment plans to identify those who might benefit from initiation of a GLP-1 receptor agonist that is indicated for CV benefit
- Confidently initiate a GLP-1 receptor agonist and develop strategies for ensuring optimal outcomes
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.
Activity no. 267720
Members are able to claim CPD activity points for 2 points through 'Quick log' on their RACGP CPD Dashboard.
#
of credits: 2
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
